Results 1 to 10 of about 131 (88)

Pregnancy outcomes following unintentional exposure to TAK-003, a live-attenuated tetravalent dengue vaccine

Expert Review of Vaccines
Background The tetravalent dengue vaccine TAK-003 is contraindicated during pregnancy. Pregnant women were excluded from TAK-003 clinical studies; however, some pregnancies occurred unintentionally.Research design and methods This post-hoc analysis of ...
Martina Rauscher
exaly   +12 more sources

TAK-003: development of a tetravalent dengue vaccine

Expert Review of Vaccines
Introduction Dengue incidence has increased over the past few decades. One tetravalent dengue vaccine based on a yellow fever backbone has been approved, but due to increased risk of severe disease in dengue-naïve recipients, its use is limited to ...
Rodrigo Deantonio, Jenny Guek Hong Low
exaly   +5 more sources

Bridging the immunogenicity of a tetravalent dengue vaccine (TAK-003) from children and adolescents to adults

Npj Vaccines, 2023
Immunobridging is an important methodology that can be used to extrapolate vaccine efficacy estimates to populations not evaluated in clinical studies, and that has been successfully used in developing many vaccines.
Inge Lefèvre, Lulu Bravo, Eduardo Lopez Medina   +2 more
exaly   +4 more sources

Immunogenicity, Safety and Efficacy of the Dengue Vaccine TAK-003: A Meta-Analysis

Vaccines
The TAK-003 dengue vaccine was licensed in Europe in December 2022, and the official recommendations from most EU countries are still under formulation. To support policymakers, we performed a meta-analysis to quantify TAK-003’s immunogenicity, efficacy ...
Maria Elena Flacco, Alessandro Bianconi, Matteo Fiore   +2 more
exaly   +5 more sources

Severe dengue hemorrhagic fever after TAK-003 dengue vaccination: A case report of a potential vaccine-associated adverse reaction

International Journal of Infectious Diseases
We report a severe dengue case that developed symptoms 5 days post-TAK-003 dengue vaccine administration. Whole-genome sequencing confirmed co-detection of all four dengue serotypes with high similarity to vaccine strains, especially DENV-2. This finding
Pinyo Rattanaumpawan, Navin Horthongkham, Kamol Suwannakarn   +2 more
exaly   +5 more sources

A Methodological Approach to Measuring the Impact of TAK-003 for the Prevention of Dengue in Dourados, Brazil: Optimizing Strategies for Public Health

Vaccines
Background/Objectives: Takeda’s tetravalent dengue vaccine TAK-003 has been approved by the Brazilian regulatory agency ANVISA for dengue disease prevention in individuals aged 4 to 60 years. Dourados, in the state of Mato Grosso do Sul, became the world’
Roberto Dias De Oliveira, Alberta Di Pasquale, Julio Croda   +2 more
exaly   +5 more sources

Efficacy of Live Attenuated Dengue Vaccines: CYD-TDV, TDV (TAK-003), and TV003/TV005

Folia Medica Indonesiana, 2021
Highlight: • Differences in the efficacy of CYD-TDV versus the other TAK-003 and TV003/TV005 were discussed. • One licensed dengue vaccine is CYD-TDV (Dengvaxia).
Yoseph Jeffry Hertanto, Bernadette Dian Novita   +1 more
doaj   +4 more sources

BRIDGING THE IMMUNOGENICITY OF A TETRAVALENT DENGUE VACCINE CANDIDATE (TAK-003) FROM CHILDREN AND ADOLESCENTS TO ADULTS

International Journal of Infectious Diseases, 2023
Intro: Dengue efficacy studies are not feasible in dengue non-endemic countries. For TAK-003, we present an immunobridging analysis to infer vaccine efficacy as determined in the DEN-301 phase 3 efficacy trial conducted in children and adolescents from ...
C. Halim, V. Tricou, F. Nordio, N. Folschweiller   +3 more
doaj   +2 more sources

Role of the dengue vaccine TAK-003 in an outbreak response: Modeling the Sri Lanka experience.

PLoS Neglected Tropical Diseases
BackgroundOutbreaks of dengue can overburden hospital systems, drastically reducing capacity for other care. The 2017 dengue serotype 2 (DENV-2) outbreak in Sri Lanka coincided with vaccination in an ongoing phase 3 efficacy trial of a tetravalent dengue
LakKumar Fernando, Randee Kastner, Pujitha Wickramasinghe, Asvini D Fernando, Dulanie Gunasekera, Van Hung Nguyen, Mengya Liu, Inge LeFevre, Derek Wallace, Nicolas Folschweiller, Shibadas Biswal   +10 more
doaj   +3 more sources

The TAK-003 story: key decisions that shaped development of a tetravalent dengue vaccine

npj Vaccines
The approved, live-attenuated tetravalent dengue vaccine TAK-003 has undergone extensive preclinical and clinical assessment. This review provides an overview of the rationale for some key decisions made during TAK-003 development.
Ian Escudero, Dieter Gniel, Shibadas Biswal, Eckhardt Petri, Gonzalo Perez, Mayuri Sharma, John Weil, Derek Wallace   +7 more
doaj   +3 more sources